Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug tested for Tough-to-Treat lung cancer

NCT ID NCT05577715

Terminated Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested an experimental drug called MORAb-202 in people with a specific type of advanced lung cancer that had spread and stopped responding to prior treatments. The goal was to see if the drug was safe and if it could shrink tumors. The trial was small and ended early.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Henry Ford Hospital

    Detroit, Michigan, 48202-2608, United States

  • Local Institution - 0001

    Marietta, Georgia, 30060, United States

  • Local Institution - 0002

    Kansas City, Missouri, 64132, United States

  • Local Institution - 0005

    Louisville, Kentucky, 40241-2832, United States

  • Local Institution - 0007

    Orange, California, 92868-3201, United States

  • Local Institution - 0010

    Orange City, Florida, 32763-8316, United States

  • Local Institution - 0011

    Charlotte, North Carolina, 28207, United States

  • Local Institution - 0012

    Ballarat Central, Victoria, 3350, Australia

  • Local Institution - 0014

    Toulon, 83056, France

  • Local Institution - 0015

    Suresnes, 92151, France

  • Local Institution - 0017

    Rouen, 76000, France

  • Local Institution - 0018

    Madrid, 28041, Spain

  • Local Institution - 0019

    Majadahonda (Madrid), M, 28222, Spain

  • Local Institution - 0020

    Málaga, MA, 29010, Spain

  • Local Institution - 0021

    Barcelona, 08036, Spain

  • Local Institution - 0022

    Murdoch, Western Australia, 6150, Australia

  • Local Institution - 0023

    Santiago, 7500921, Chile

  • Local Institution - 0025

    Barcelona, 08035, Spain

  • Local Institution - 0026

    Santiago de Compostela, 15706, Spain

  • Local Institution - 0027

    Recoleta, 8420383, Chile

  • Local Institution - 0028

    Providencia, SA, 7500653, Chile

  • Local Institution - 0030

    Independencia, 8380456, Chile

  • Local Institution - 0031

    Seville, 41013, Spain

  • Local Institution - 0033

    Fairfax, Virginia, 22031-4629, United States

  • Local Institution - 0034

    Arlington, Texas, 76012-2510, United States

  • Local Institution - 0035

    Lone Tree, Colorado, 80124, United States

  • Local Institution - 0036

    Roeselare, 8800, Belgium

  • Local Institution - 0038

    Villejuif, 94805, France

  • Local Institution - 0039

    Mons, WHT, 7000, Belgium

  • Local Institution - 0040

    Wollongong, NS, 2500, Australia

  • Local Institution - 0043

    Clermont, Florida, 34711-6699, United States

  • Local Institution - 0044

    Silver Spring, Maryland, 20904-7917, United States

  • Local Institution - 0045

    Flower Mound, Texas, 75028-1713, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG